MARLBOROUGH, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced that the newly established Queensland Spatial Biology Centre (QSBC), located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial biology platform as the core technology to revolutionize the way cancer and other debilitating diseases are diagnosed and treated. The PhenoCycler-Fusion platform facilitates the understanding of the cellular compositions, neighbor ...

MARLBOROUGH, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the establishment of its Scientific Advisory Board (SAB) to provide strategic guidance and consult on the Company's efforts to deliver spatial biology solutions for the life sciences industry, from discovery to diagnostics. The initial members of Akoya's Scientific Advisory Board are: Garry Nolan, Ph.D., Rachford and Carlota A. Harris Professor in the Department of Path ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 8th:Akoya Biosciences, Inc. (AKYA) : This life-sciences technology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.4% over the last 60 days.Akoya’s shares gained 11.9% over the last three months compared with the S&P 500’s advance of 8%. The company possesses a Momentum Score  of A.Alpha Tau Medical Ltd. (DRTS) : This clinical-sta ...

MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were described in two recent Nature publications MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Priyam Shah - Head of Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants Edmund Tu - Morgan Stanley Kyle Mikson - Canaccord Genuity Timothy Chiang - Capital One Mason Carrico - Stephens Inc. Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Akoya Biosciences Incorporated Third Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-55 ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Priyam Shah - Head of Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Lucas Baranowski - UBS Rachel Vatnsdal - JPMorgan Chase Mark Massaro - BTIG Edmund Tu - Morgan Stanley Tim Chiang - Capital One David Westenberg - Piper Sandler Mason Carrico - Stephens Inc. Operator Good day and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-5586242 ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Priyam Shah - Investor Relations Brian McKelligon - Chief Executive Officer John Ek - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Mason Carrico - Stephens Inc Ruizhi Qin - JPMorgan Vivian Bais - BTIG Kyle Mikson - Canaccord Genuity David Westenberg - Piper Sandler Lucas Baranowski - UBS Operator Good day and thank you for standing by. Welcome to the Akoya Biosc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-558624 ...